SOX10 and neoplasm: We have also corroborated this by immunohistochemical analysis of primary patient tumor cores where we observed no differences in AR expression between HER2, Luminal A/B, or TNBC samples despite the TNBC subtype showing a significant increase in SOX10 expression (Figure 8).